Abstract
Small molecules targeting p53 represent an emerging group of potentially useful agents for the improvement of antitumor therapy. These modulators include agents that activate wild-type p53 or reactivate mutant p53 and inhibitors of p53 functions. Preclinical evidences support the interest of combination strategies with conventional antitumor agents.
Original language | English |
---|---|
Pages (from-to) | 856-868 |
Number of pages | 13 |
Journal | Mini-Reviews in Medicinal Chemistry |
Volume | 8 |
Issue number | 9 |
DOIs | |
Publication status | Published - 2008 |
Keywords
- Apoptosis
- Cancer cells
- Drug combination
- Histone deacetylase inhibitors
- Nutlins
- p53
- Pifithrins
- Ubiquitin ligase inhibitors
ASJC Scopus subject areas
- Medicine (miscellaneous)
- Chemistry(all)
- Pharmacology